Vitrakvi, Daurismo Approvals Put US FDA On Brink Of Another Record
Executive Summary
New oncologics bring CDER’s novel agent approvals count to 53 for the year.
You may also be interested in...
Astellas Stays Ahead of Daiichi Sankyo In AML With CHMP Nod For Xospata
A positive opinion for its FLT3 inhibitor for acute myeloid leukemia gives Astellas a further advantage over its Japanese competitor's same-class offering, quizartinib.
Keeping Track: A Quintet Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
EU Accelerated Assessment – Hard To Get, Hard To Keep
It’s hard enough in the first place for companies to persuade the European Medicines Agency that their planned marketing authorization application should be fast-tracked. Many are also finding that after accelerated assessment is granted, it is taken away during the actual review.